Salta al contenuto principale
Passa alla visualizzazione normale.

CHIARA BRANDO

Pubblicazioni

Data Titolo Tipologia Scheda
2023 Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD) Articolo in rivista Vai
2023 Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay Articolo in rivista Vai
2023 Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? Articolo in rivista Vai
2023 Potential agnostic role of BRCA alterations in patients with several solid tumors: One for all, all for one? Articolo in rivista Vai
2023 Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab Articolo in rivista Vai
2023 Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer Articolo in rivista Vai
2023 KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study Articolo in rivista Vai
2022 Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is Strength Articolo in rivista Vai
2022 Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors? Articolo in rivista Vai
2022 Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors Articolo in rivista Vai
2022 BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: Looking for the hidden meaning Articolo in rivista Vai
2022 Liquid biopsy and immunotherapy: is all that glitter gold? Capitolo o Saggio Vai
2022 Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer? Articolo in rivista Vai
2022 Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer Articolo in rivista Vai
2022 MUTYH-associated tumor syndrome: The other face of MAP Articolo in rivista Vai
2021 Role of the HIPPO pathway as potential key player in the cross talk between oncology and cardiology Articolo in rivista Vai
2021 Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge Articolo in rivista Vai
2021 Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs) Articolo in rivista Vai
2021 Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome Articolo in rivista Vai
2021 Prognostic role of plasma pd‐1, pd‐l1, pan‐btn3as and btn3a1 in patients affected by metastatic gastrointestinal stromal tumors: Can immune checkpoints act as a sentinel for short‐term survival? Articolo in rivista Vai
2021 Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors Review essay (rassegna critica) Vai
2021 POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes Review essay (rassegna critica) Vai
2020 A “lymphocyte microrna signature” as predictive biomarker of immunotherapy response and plasma pd-1/pd-l1 expression levels in patients with metastatic renal cell carcinoma: Pointing towards epigenetic reprogramming Articolo in rivista Vai
2020 Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions Articolo in rivista Vai
2020 Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 Articolo in rivista Vai
2020 BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients Articolo in rivista Vai